Acknowledgements
The authors would like to thank the patients, investigators, and study teams who were involved in the tofacitinib UC program. This study was sponsored by Pfizer. Medical writing support, under the direction of the authors, was provided by Robyn Wilson, BSc, CMC Connect, a division of IPG Health Medical Communications, funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (